Kandy Therapeutics Limited

Nerre Therapeutics Limited

Mary Kerr

Mike Trower

David Elder

Monica Lazaro

Derek Bush

Stephen Pawsey

The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl) hexahydropyrazino [2,1-c] [1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.

Method of treatment of symptoms of menopause

This invention relates to the new use of neurokinin-1 receptor antagonists as a treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs. Specifically, when the mechanical injury to the lungs is induced by mechanical ventilation or by the act of coughing in a subset of patients with pulmonary fibrosis conditions who cough. The invention further relates to pharmaceutical compositions comprising neurokinin-1 receptor antagonist drugs and to combinations for such uses.

Uses

The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.

Method of treating certain sex hormone-dependent diseases administering a soft gelatin capsule comprising NK1 and NK3 receptors antagonists

Soft gelatin capsule formulation

Growing community of inventors

Stevenage, United Kingdom

Mary Kerr